Table 4.
Comparison of CgA change according to treatment response in other studies
| Serum CgA determination | CgA increase | CgA stable | CgA decrease | Concordance between event and CgA-change | ||
|---|---|---|---|---|---|---|
| Welin et al. [11] | Recurred midgut carcinoid tumors | CgA > 4 nmol/L | 28/33 (85) | - | - | - |
| Sondenaa et al. [12] | After surgical resection of midgut carcinoid tumors | CgA > 30 nmol/L | 7/7 (100) | - | - | - |
| Baudin et al. [13] | After disease progression | CgA > 100 U/I | 5/6 (85) | - | - | - |
| Jensen et al. [14] | Median F/U: 12 mo | SD: within ± 25% | 83/97 (85) | 204/279 (73) | 39/50 (78) | 76% |
| PD > +25% | ||||||
| PR < -25% | ||||||
| Walter et al. [15] | Median F/U: 27 mo | SD: within ± 50% | 28/50 (56) | 22/47 (47) | 7/15 (46) | 51% |
| PD > +50% | ||||||
| PR < -50% | ||||||
| Nehar et al. [16] | Median F/U: 33 mo | SD: within ± 25% | 89% | 78% | 79% | 80% |
| PD > +25% | ||||||
| PR < -25% | ||||||
| Chou et al. [17] | Asian patients, median F/U: 12 mo | Responder: decrease ≥ 20% | 6/6 (100) | 5/5 (100) | 100% | |
| Non-responder: decrease < 20% |
Values are presented as number (%) unless otherwise indicated. CgA, chromogranin A; SD, stable disease; PD, progressive disease; PR, partial response.